Biogen teams up with Alkermes to develop MS candidate ALKS 8700


Biogen and Alkermes plc enter into a global license and collaboration agreement to develop and commercialize ALKS 8700 for the treatment of relapsing forms of multiple sclerosis . Under the terms of the agreement, Alkermes will receive $28M upfront, milestones up to $200M and mid-teens royalties on global net sales.



from Biotech News